December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.
First, let’s talk about logistics. Back in April,
Rolling Stone reported on the concept of immunity certificates or passports some type of documentation (electronic or paper) that would serve as proof that a person is immune from the novel coronavirus. And though much has changed since then both in terms of understanding the virus and now having two safe and effective vaccines Dr. L.J. Tan, an immunologist and the chief strategy officer of the Immunization Action Coalition (IAC), says that policies like these are still premature from a scientific standpoint.
Specifically, it is not yet known how long immunity from the Covid vaccine will last. “We haven’t got six months, nine months of duration of protection data yet,” Tan tells
Vice chancellor: Performing together, CU Anschutz researchers accelerated SARS-CoV-2 discovery
Working amid laboratory shutdowns and strict COVID-19 protocols, the medical scientists on the University of Colorado Anschutz Medical Campus responded to a global pandemic in 2020 in groundbreaking fashion.
Rapidly joining an effort to understand and battle SARS-CoV-2, CU Anschutz researchers created an antibody test, advanced novel therapies, guided a state public-health response and launched a database that can accelerate discoveries in laboratories around the world.
And that’s just a fraction of the research community’s accomplishments during a time of need.
“We’ve gone through a tumultuous few months to be sure,” said Thomas Flaig, MD, who took the reins as vice chancellor for research just as the pandemic struck in March. But it brought the campus together in unprecedented ways, Flaig said, during the inaugural State of Research address on Dec. 8.
By
As a budding school teacher, Mimi Hayes (right) was having a stroke at age 22, medical professionals kept explaining her symptoms away and sending her home until her mom (left) stepped in. (Courtesy of Mimi Hayes)
This story is from The Pulse, a weekly health and science podcast.
Subscribe on Apple Podcasts, Stitcher or wherever you get your podcasts.
I went on a blind date. OKCupid, I think.
He was your typical finance bro: crew cut, one of those fleece vests. We ordered appetizers. My head was throbbing like crazy. All I could think about was getting through this and getting home. My mom picked me up after because my car had broken down that week.
E-Mail
AURORA, Colo. (Dec. 15, 2020) - Researchers at the University of Colorado Anschutz Medical Campus have discovered that fructose stimulates the release of vasopressin, a hormone linked to obesity and diabetes. They also found that water can suppress the hormone and alleviate these conditions in mice. The clinical significance of this work is that it may encourage studies to evaluate whether simple increases in water intake may effectively mitigate obesity and metabolic syndrome, said the study s lead author Miguel A. Lanaspa, PhD, an associate professor at the University of Colorado School of Medicine specializing in renal disease and hypertension.
The study was published today in the journal